Literature DB >> 7923877

Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumour necrosis factor-alpha (TNF-alpha) activate human alveolar macrophages to inhibit growth of Mycobacterium avium complex.

K Suzuki1, W J Lee, T Hashimoto, E Tanaka, T Murayama, R Amitani, K Yamamoto, F Kuze.   

Abstract

We investigated the effects of certain macrophage-active cytokines on the phagocytosis and growth inhibition of Mycobacterium avium complex (MAC) by human alveolar macrophages (AM). We also evaluated the effects of pretreatment with each cytokine on the superoxide anion release (O2-) from AM. The cytokines that we used were recombinant GM-CSF, natural type TNF-alpha, recombinant interferon-gamma (IFN-gamma), and recombinant IL-2. We found that phagocytosis by the various cytokine-stimulated AM was similar to that of unstimulated AM. On the other hand, significant growth inhibition of MAC was observed in the macrophages treated with GM-CSF or TNF-alpha, while no growth inhibition of MAC was observed in the macrophages treated with IFN-gamma or IL-2. Pretreatment with all cytokines tested enhanced the O2- release from AM, but there was no correlation between the enhancement of O2- release and the growth inhibition of MAC. Thus, we concluded that GM-CSF or TNF-alpha could activate AM to inhibit growth of MAC, probably not through the enhanced production of reactive oxygen intermediates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923877      PMCID: PMC1534174          DOI: 10.1111/j.1365-2249.1994.tb06625.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Reduced intracellular growth of mycobacteria in human macrophages cultivated at physiologic oxygen pressure.

Authors:  P R Meylan; D D Richman; R S Kornbluth
Journal:  Am Rev Respir Dis       Date:  1992-04

2.  Strain- and donor-related differences in the interaction of Mycobacterium avium with human monocytes and its modulation by interferon-gamma.

Authors:  H Shiratsuchi; J L Johnson; H Toba; J J Ellner
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

3.  Oxidative and non-oxidative intracellular killing of Mycobacterium avium complex.

Authors:  L E Bermudez; L S Young
Journal:  Microb Pathog       Date:  1989-10       Impact factor: 3.738

4.  Growth of Mycobacterium avium in human monocytes: identification of cytokines which reduce and enhance intracellular microbial growth.

Authors:  M Denis
Journal:  Eur J Immunol       Date:  1991-02       Impact factor: 5.532

5.  Growth inhibition of Mycobacterium avium complex in human alveolar macrophages by the combination of recombinant macrophage colony-stimulating factor and interferon-gamma.

Authors:  R M Rose; J M Fuglestad; L Remington
Journal:  Am J Respir Cell Mol Biol       Date:  1991-03       Impact factor: 6.914

6.  Oxidative inactivation of alpha 1-proteinase inhibitor by alveolar macrophages from healthy smokers requires the presence of myeloperoxidase.

Authors:  B Wallaert; B Gressier; C Aerts; C Mizon; C Voisin; J Mizon
Journal:  Am J Respir Cell Mol Biol       Date:  1991-11       Impact factor: 6.914

7.  [Clinical features of the patients with "secondary infection" of Mycobacterium avium complex--Radiographic pattern of progressions in the patients with and without underlying pulmonary conditions].

Authors:  E Tanaka; R Amitani; F Kuze
Journal:  Kekkaku       Date:  1993-01

8.  Infection with Mycobacterium avium complex in patients without predisposing conditions.

Authors:  D S Prince; D D Peterson; R M Steiner; J E Gottlieb; R Scott; H L Israel; W G Figueroa; J E Fish
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

9.  Bidirectional effects of cytokines on the growth of Mycobacterium avium within human monocytes.

Authors:  H Shiratsuchi; J L Johnson; J J Ellner
Journal:  J Immunol       Date:  1991-05-01       Impact factor: 5.422

10.  Interferon decreases the growth inhibition of Mycobacterium avium-intracellulare complex by fresh human monocytes but not by culture-derived macrophages.

Authors:  D K Blanchard; M B Michelini-Norris; J Y Djeu
Journal:  J Infect Dis       Date:  1991-07       Impact factor: 5.226

View more
  7 in total

1.  Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans.

Authors:  Ryan M Kelly; Jianmin Chen; Lauren E Yauch; Stuart M Levitz
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

2.  Roles for tumor necrosis factor alpha and nitric oxide in resistance of rat alveolar macrophages to Legionella pneumophila.

Authors:  S J Skerrett; T R Martin
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

3.  Salmonella induced IL-23 and IL-1beta allow for IL-12 production by monocytes and Mphi1 through induction of IFN-gamma in CD56 NK/NK-like T cells.

Authors:  Diederik van de Wetering; Roelof A de Paus; Jaap T van Dissel; Esther van de Vosse
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

4.  Cytokine-mediated activation of macrophages from Mycobacterium bovis BCG-resistant and -susceptible mice: differential effects of corticosterone on antimycobacterial activity and expression of the Bcg gene (Candidate Nramp).

Authors:  D H Brown; W LaFuse; B S Zwilling
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

5.  Potential therapeutic effect of ninjinyoeito for the treatment of pulmonary nontuberculous mycobacterial infections: A case report.

Authors:  Tatsuya Nogami
Journal:  J Family Med Prim Care       Date:  2019-09-30

Review 6.  The Impact of Alcohol Use Disorder on Tuberculosis: A Review of the Epidemiology and Potential Immunologic Mechanisms.

Authors:  Gregory W Wigger; Tara C Bouton; Karen R Jacobson; Sara C Auld; Samantha M Yeligar; Bashar S Staitieh
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 8.786

7.  Pilot quasi-randomized controlled study of herbal medicine Hochuekkito as an adjunct to conventional treatment for progressed pulmonary Mycobacterium avium complex disease.

Authors:  Yasunori Enomoto; Eri Hagiwara; Shigeru Komatsu; Ryuichi Nishihira; Tomohisa Baba; Hideya Kitamura; Akimasa Sekine; Atsuhito Nakazawa; Takashi Ogura
Journal:  PLoS One       Date:  2014-08-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.